APA (7th ed.) Citation
(2026). Strategic selection of MDM2 inhibitors enhances the efficacy of FAK inhibition in mesothelioma based on TP53 genotype. PLOS ONE.
Chicago Style (17th ed.) Citation
"Strategic Selection of MDM2 Inhibitors Enhances the Efficacy of FAK Inhibition in Mesothelioma Based on TP53 Genotype." PLOS ONE 2026.
MLA (9th ed.) Citation
"Strategic Selection of MDM2 Inhibitors Enhances the Efficacy of FAK Inhibition in Mesothelioma Based on TP53 Genotype." PLOS ONE, 2026.
Warning: These citations may not always be 100% accurate.